Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …

Answer questions and earn CME/CNE Pancreatic cancer is currently one of the deadliest of
the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and …

Purpose To provide evidence-based recommendations to oncologists and others on
potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO …

Substantial progress has been made in our understanding of the biology of pancreatic
cancer, and advances in patients' management have also taken place. Evidence is …

Background The benefits of preoperative biliary drainage, which was introduced to improve
the postoperative outcome in patients with obstructive jaundice caused by a tumor of the …

Background Initial recurrence mapping of resected pancreatic ductal adenocarcinoma
(PDAC) could help in stratifying patient subpopulations for optimal postoperative follow-up …